SlideShare a Scribd company logo
3
Most read
9
Most read
11
Most read
SEMINAR PRESENTATION ON
21 CFR Part 822 Post Marketing Surveillance
R. C. PATELINSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
PRESENTED BY:
Mr. MayurAnil Patil
M.PHARM 1ST YEAR
MRA09
GUIDED BY :
DR. P. P. NERKAR
PROFESSORAND
HEAD OF RADEPARTMENT
Post Marketing Surveillance
 The term Pharmacovigilance is used for the Post
Marketing Surveillance of a drug. Post Marketing
Surveillance helps to monitor the side effects of a
drug after it has been launched in the market for
the use of the patients.
 Post Marketing Surveillanceis another term used
for Pharmacovigilance.
Table of Contents
Subpart A - General Provisions
$ 822.1 What does this part cover?
$822.2 What is the purpose of this part?
§ 822.3 How do you define the terms used in this part?
$822.4 Does this part apply to me ?
Subpart B – Notification
§ 822.5 How will I know if I must conduct post market surveillance?
§ 822.6 When will you notify me that I am required to conduct post
market surveillance?
$822.7 What should I do if I do not agree that postmarket
surveillance is appropriate?
Subpart C-Post-Market Surveillance Plan•
§ 822.8When, where, and how must I submit my postmarket surveillance plan?
§ 822.9What must I include in my submission?
§ 822.10What must I include in my surveillance plan?
§ 822.11What should I consider when designing my plan to conduct postmarket surveillance?
§ 822.12Do you have any information that will help me prepare my submission or design my
postmarket surveillance plan?
§ 822.13 [Reserved]
§ 822.14May I reference information previously submitted instead of submitting it again?
§ 822.15How long must I conduct postmarket surveillance of my device?
Subpart D-FDA Review and Action.
§ 822.16What will you consider in the review of my submission?
§ 822.17How long will your review of my submission take?
§ 822.18How will I be notified of your decision?
§ 822.19What kinds of decisions may you make?
§ 822.20What are the consequences if I fail to submit a
postmarket surveillance plan, my plan is disapproved and I fail to
submit a new plan, or I fail to conduct surveillance in accordance
with my approved plan?
§ 822.21What must I do if I want to make changes to my
postmarket surveillance plan after you have approved it?
§ 822.22What recourse do I have if I do not agree with your
decision?
§ 822.23Is the information in my submission considered
confidential?
Subpart E-Responsibilities of Manufacturers.
§ 822.24What are my responsibilities once I am notified that I am required to
conduct postmarket surveillance?
§ 822.25What are my responsibilities after my postmarket surveillance plan has
been approved?
§ 822.26If my company changes ownership, what must I do?
§ 822.27If I go out of business, what must I do?
§ 822.28If I stop marketing the device subject to postmarket surveillance, what
must I do?
Subpart F-Waivers and Exemptions.
§ 822.29May I request a waiver of a specific requirement of this part?
§ 822.30May I request exemption from the requirement to conduct postmarket surveillance?
Subpart G-Records and Reports.
§ 822.31What records am I required to keep?
§ 822.32What records are the investigators in my surveillance plan required to keep?
§ 822.33How long must we keep the records?
§ 822.34What must I do with the records if the sponsor of the plan or an investigator in the
plan changes?
§ 822.35Can you inspect my manufacturing site or other sites involved in my postmarket
surveillance plan?
§ 822.36Can you inspect and copy the records related to my postmarket surveillance plan?
§ 822.37Under what circumstances would you inspect records identifying subjects?
§ 822.38What reports must I submit to you?
Subpart A: General Provisions
$ 822.1 What does this part cover?
This part implements section 522 of the Federal Food, Drug, and
Cosmetic Act (the act) by providing procedures and requirements for
post market surveillance of class II and class III devices that meet any
of the following criteria:
• Failure of the device that would likely to have serious adverse
health consequences
• device is intended to be implanted in the human body for more
than 1 year
$822.2 What is the purpose of this part?
∙to implement our post market surveillance authority to maximize the
likely hood that post market surveillance plans will result in the
collection of useful data that can reveal unforeseen ADRs.
§ 822.3 How do you define the terms used in this part?
• Act means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301
et seq., as amended.
• Unique device identifier (UDI) means an identifier that adequately
identifies a device through its distribution
• Manufacturer
• Investigator
•PMS
$822.4 Does this part apply to me ?
If we have ordered you to conduct post market surveillance of a
medical device under section 522 of the act, this part applies to
you, if the MD’s intended use is any:
• Implant for more than 1 year
• Support or sustain life
Subpart B: Notification
§ 822.5 How will I know if I must conduct post market
surveillance?
• FDA will send you a letter (the post market surveillance
order) notifying you of the requirement to conduct post
market surveillance.
• FDA will specify the device(s) subject to the surveillance
order and the reason for requiring post market surveillance
of the device under section522 of the act.
§ 822.6 When will you notify me that I am required to
conduct post market surveillance?
• FDA will notify you as soon as we have determined that
postmarket surveillance of your device is necessary, based
on the identification of a surveillance question.
$822.7 What should I do if I do not agree that postmarket
surveillance is appropriate?
• Requesting a meeting with the Director, Office of
Surveillance and Biometrics
• Requesting review by the Medical Devices Dispute
Resolution Panel of the Medical Devices Advisory Committee.
Subpart C-Post-Market Surveillance Plan
§ 822.8 When, where, and how must I submit my
postmarket surveillance plan?
You must submit your plan to conduct post-market
surveillance within 30days of the date you receive the post-
market surveillance order to the following concerned
authorities:
• Center for Biologics Evaluation and Research, FDA
• Center for Drug Evaluation and Research, FDA
• Document Mail Center for Radiological Devices
§ 822.9 What must I include in my submission?
1.Organizational/administrative information:
• Your name and address.
• Generic and trade names of your device
• Name and address of the contact person for the submission
• Premarket application/submission number and device identifiers
• Description of the device
• Product codes and a list of all relevant model numbers
• Indications for use and claims for the device
2. Post-market surveillance plan
3. Designated person information
• Name, address, and telephone number
• Experience and qualifications
$822.10 What must I include in my surveillance plan?
The plan objectives.
• Subject of study (humans, animals).
• Approach or methodology.
• Sample size
• Data collection plan.
• Consent document
• IRB approval
• Content and timing of reports
• Patient follow up plans
• Duration
§822.11 What should I consider when designing my plan to
conduct postmarket surveillance?
You must design your surveillance to address the post-market
surveillance question identified in the order you received.
§ 822.12 Do you have any information that will help me
prepare my submission or design my postmarket
surveillance plan?
Guidance documents that discuss our current thinking on
preparing a post-market surveillance submission and
designing a post-market surveillance plan are available on
the Center for Devices and Radiological Health’s website,
the Food and Drug Administration main website
§ 822.14 May I reference information previously submitted
instead of submitting it again?
Yes, you may reference information that you have submitted in
premarket submissions as well as other post-market surveillance
submissions, with document and page number.
§ 822.15 How long must I conduct post-market surveillance of
my device?
The length of post-market surveillance will depend on the post-
market surveillance question identified. It may be of 36 months
or more depending on satisfying information.
Subpart D-FDA Review and Action.
§ 822.16 What will you consider in the review of my submission?
First, we will determine that the submission is administratively
complete. Then, in accordance with the law, we must determine
whether the designated person has appropriate qualifications and
experience to conduct the surveillance and whether the surveillance
plan will result in the collection of useful data that will answer the
surveillance question.
§ 822.17 How long will your review of my submission take?
We will review your submission within 60 days of receipt.
§ 822.18 How will I be notified of your decision?
We will send you a letter notifying you of our decision and identifying
any action you must take.
§ 822.19 What kinds of decisions may you make?
Subpart E—Responsibilities of Manufacturers
§ 822.24 What are my responsibilities once I am notified that I am required to conduct postmarket
surveillance?
You must submit your plan to conduct postmarket surveillance to us within 30 days from receipt of the order
(letter) notifying you that you are required to conduct postmarket surveillance of a device. The manufacturer
shall commence surveillance not later than 15 months after the day the order was issued. [88 FR 16880, Mar.
21, 2023]
§ 822.25 What are my responsibilities after my postmarket surveillance plan has been approved?
After we have approved your plan, you must conduct the postmarket surveillance of your device in accordance
with your approved plan. This means that you must ensure that:
(a) Postmarket surveillance is initiated in a timely manner;
(b) The surveillance is conducted with due diligence;
(c) The data identified in the plan is collected;
(d) Any reports required as part of your approved plan are submitted to us in a timely manner;
§ 822.26 If my company changes ownership, what must I do?
You must notify us within 30 days of any change in ownership of your company.
§ 822.27 If I go out of business, what must I do?
You must notify us within 30 days of the date of your decision to close your business.
§ 822.28 If I stop marketing the device subject to postmarket surveillance, what must I do?
You must continue to conduct postmarket surveillance in accordance with your approved plan even if you no
longer market the device.
Subpart F—Waivers and Exemptions
§ 822.29 May I request a waiver of a specific
requirement of this part?
You may request that we waive any specific requirement of this
part. You may submit your request, with supporting
documentation, separately or as a part of your postmarket
surveillance submission to the address in § 822.8.
§ 822.30 May I request exemption from the
requirement to conduct postmarket surveillance?
You may request exemption from the requirement to conduct
postmarket surveillance for your device or any specific model of
that device at any time.
Subpart G—Records and Reports
§ 822.31 What records am I required to keep?
You must keep copies of:
(a) All correspondence with your investigators or FDA, including required reports;
(b) Signed agreements from each of your investigators, if your surveillance plan uses
investigators, stating the commitment to conduct the surveillance in accordance with the
approved plan, any applicable FDA regulations, and any conditions of approval for your plan,
such as reporting requirements;
(c) Your approved postmarket surveillance plan, with documentation of the date and reason for
any deviation from the plan;
(d) All data collected and analyses conducted in support of your postmarket surveillance plan;
§ 822.32 What records are the investigators in my surveillance plan required to keep?
Your investigator must keep copies of:
(a) All correspondence between investigators, FDA, the manufacturer, and the designated
person, including required reports.
(b) The approved postmarket surveillance plan, with documentation of the date and reason for
any deviation from the plan.
(c) All data collected and analyses conducted at that site for postmarket surveillance.
(d) Any other records that we require to be maintained by regulation or by order.
§ 822.33 How long must we keep the records?
You, the designated person, and your investigators must keep all records for a period of 2 years
after we have accepted your final report, unless we specify otherwise.
§ 822.34 What must I do with the records if the sponsor of the plan
or an investigator in the plan changes?
If the sponsor of the plan or an investigator in the plan changes, you must ensure that all
records related to the postmarket surveillance have been transferred to the new sponsor or
investigator and notify us within 10 working days of the effective date of the change.
822.36 Can you inspect and copy the records related to my
postmarket surveillance plan?
We may, at a reasonable time and in a reasonable manner, inspect and copy any records
pertaining to the conduct of postmarket surveillance that are required to be kept by this
regulation.
§ 822.37 Under what circumstances would you inspect records
identifying subjects?
We can inspect and copy records identifying subjects under the same
circumstances that we can inspect any records relating to postmarket
surveillance.
§ 822.38 What reports must I submit to you?
You must submit interim and final reports as specified in your approved
postmarket surveillance plan. In addition, we may ask you to submit additional
information when we believe that the information is necessary for the protection
of the public health and implementation of the act. We will also state the reason
or purpose for the request and how we will use the information.
THANK
YOU

More Related Content

PPTX
21 CFR PART 50.pptx
PPTX
Preclinical and Clinical Development Consideration in Herbals & Biologics in USA
PPTX
Medical devices CHINA
PPTX
Nutritional labelling & European Regulation on Novel Foods and Novel Food Ing...
PPTX
Cfr 21 part 312
PPTX
Development and Regulatory Approval of Biologics in European Union (Investiga...
PDF
ISO 14155 Clinical investigation of medical devices for human subjects- Good ...
PPTX
Medical Device Exemption and Post Marketing Survelliance
21 CFR PART 50.pptx
Preclinical and Clinical Development Consideration in Herbals & Biologics in USA
Medical devices CHINA
Nutritional labelling & European Regulation on Novel Foods and Novel Food Ing...
Cfr 21 part 312
Development and Regulatory Approval of Biologics in European Union (Investiga...
ISO 14155 Clinical investigation of medical devices for human subjects- Good ...
Medical Device Exemption and Post Marketing Survelliance

What's hot (20)

PPTX
Organization and Structure Of EMA/EDQM ,ASMF,IMPD and Marketing Authorization...
PPTX
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...
PPTX
Regulations of Import, Sale and Manufacture of Neutraceuticals in India
PPTX
Regulation of medical device in japan
PPTX
Premarket Notification 510(k) for Biologics [Autosaved].pptx
PPTX
REGULATORY CONSIDERATIONS IN JAPAN.pptx
PDF
ISO 14155.pdf
PPTX
Quality, Safety and Legislation for herbal products in USA.pptx
PPTX
Drug Registration in ASEAN Countries.pptx
PPTX
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
PPTX
GHTF
PPTX
Plasma master file
PPTX
GCC Regulatory MAA & post approval requirements (Saudi Arabia & UAE) unit-5 R...
PPTX
IDE Application Process and Best Practices
PPTX
Organization structure of EMA and EDQM active Substance Master File.pptx
PPTX
Post marketing surveillance in Japan, legislation and.pptx
PPTX
Cfr code of federal regulations-1 (1)
PPTX
BIOLOGICS IN EUROPEAN UNION SLIDESHARE..
PPTX
GHTF Group 1
PPTX
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
Organization and Structure Of EMA/EDQM ,ASMF,IMPD and Marketing Authorization...
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...
Regulations of Import, Sale and Manufacture of Neutraceuticals in India
Regulation of medical device in japan
Premarket Notification 510(k) for Biologics [Autosaved].pptx
REGULATORY CONSIDERATIONS IN JAPAN.pptx
ISO 14155.pdf
Quality, Safety and Legislation for herbal products in USA.pptx
Drug Registration in ASEAN Countries.pptx
INVESTIGATIONAL DEVICE EXEMPTIONS.pptx
GHTF
Plasma master file
GCC Regulatory MAA & post approval requirements (Saudi Arabia & UAE) unit-5 R...
IDE Application Process and Best Practices
Organization structure of EMA and EDQM active Substance Master File.pptx
Post marketing surveillance in Japan, legislation and.pptx
Cfr code of federal regulations-1 (1)
BIOLOGICS IN EUROPEAN UNION SLIDESHARE..
GHTF Group 1
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptx
Ad

Similar to 21 CFR Part 822 Post Marketing Surveillance.pptx (20)

PPTX
Medical device regulations
PPTX
Q1 Medical Devices Regulation - practical consequences for manufacturers
PDF
Medical devices: 7 steps to CE-mark, and post-market surveillance
PPTX
Malaysia Medical Devices Regulations
PDF
Guidance for Industry and FDA Staff
PPTX
New legal obligations and liability under MDR and IVDR
PPTX
Medical device regulations 510k
PPTX
summary of indian medical device rule 2017
PPTX
Regulation Governing Clinical Trials In India,USA and Europe.
PPTX
Point of-care, biosensors & mobile diagnostics europe 2019
PPTX
MDR and class I medical devices presentation
PPTX
New legal obligations under MDR and IVDR
PPTX
medical device regulatory approval in USA
PDF
Medical devices for biosimilars
PDF
UDI: What & How within the overall Medical Device value chain
PPTX
quality-guidelines.pptx quality guide quality guide quality guide quality gui...
PDF
Medical device approval chart for Mexico - Emergo
PDF
Strategies for Device Approval in China, India, South Korea and Australia
PPTX
rules, regulation and guideline for medical devices
PDF
AdvaMed 510(k) Submissions Workshop: How to Assemble A Bullet Proof 510(k) Su...
Medical device regulations
Q1 Medical Devices Regulation - practical consequences for manufacturers
Medical devices: 7 steps to CE-mark, and post-market surveillance
Malaysia Medical Devices Regulations
Guidance for Industry and FDA Staff
New legal obligations and liability under MDR and IVDR
Medical device regulations 510k
summary of indian medical device rule 2017
Regulation Governing Clinical Trials In India,USA and Europe.
Point of-care, biosensors & mobile diagnostics europe 2019
MDR and class I medical devices presentation
New legal obligations under MDR and IVDR
medical device regulatory approval in USA
Medical devices for biosimilars
UDI: What & How within the overall Medical Device value chain
quality-guidelines.pptx quality guide quality guide quality guide quality gui...
Medical device approval chart for Mexico - Emergo
Strategies for Device Approval in China, India, South Korea and Australia
rules, regulation and guideline for medical devices
AdvaMed 510(k) Submissions Workshop: How to Assemble A Bullet Proof 510(k) Su...
Ad

More from Mayur Patil (7)

PPTX
CLINICAL_RESEARCH_REGULATIONS_IN_EUROPIAN_UNION_(_EMA[1] - Read-Only.pptx
PPTX
Responsibilities of CRO in clinical research
PPTX
WHO Guidelines On Nutrition.............
PPTX
ICMR'S ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH.pptx
PPTX
21 CFR part 11- ELECTRONIC RECORDS; ELECTRONIC SIGNATURES
PPTX
GMP for Nutraceuticals...................
PPTX
post market notification and approval.pptx
CLINICAL_RESEARCH_REGULATIONS_IN_EUROPIAN_UNION_(_EMA[1] - Read-Only.pptx
Responsibilities of CRO in clinical research
WHO Guidelines On Nutrition.............
ICMR'S ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH.pptx
21 CFR part 11- ELECTRONIC RECORDS; ELECTRONIC SIGNATURES
GMP for Nutraceuticals...................
post market notification and approval.pptx

Recently uploaded (20)

PDF
The Lost Whites of Pakistan by Jahanzaib Mughal.pdf
PDF
Origin of periodic table-Mendeleev’s Periodic-Modern Periodic table
PPTX
PPT- ENG7_QUARTER1_LESSON1_WEEK1. IMAGERY -DESCRIPTIONS pptx.pptx
PDF
O7-L3 Supply Chain Operations - ICLT Program
PPTX
Pharmacology of Heart Failure /Pharmacotherapy of CHF
PDF
Physiotherapy_for_Respiratory_and_Cardiac_Problems WEBBER.pdf
PPTX
master seminar digital applications in india
PDF
Business Ethics Teaching Materials for college
PDF
O5-L3 Freight Transport Ops (International) V1.pdf
PDF
ANTIBIOTICS.pptx.pdf………………… xxxxxxxxxxxxx
PDF
Mark Klimek Lecture Notes_240423 revision books _173037.pdf
PDF
Saundersa Comprehensive Review for the NCLEX-RN Examination.pdf
PPTX
Week 4 Term 3 Study Techniques revisited.pptx
PPTX
GDM (1) (1).pptx small presentation for students
PDF
102 student loan defaulters named and shamed – Is someone you know on the list?
PDF
Basic Mud Logging Guide for educational purpose
PPTX
Introduction to Child Health Nursing – Unit I | Child Health Nursing I | B.Sc...
PDF
2.FourierTransform-ShortQuestionswithAnswers.pdf
PDF
Pre independence Education in Inndia.pdf
PPTX
Microbial diseases, their pathogenesis and prophylaxis
The Lost Whites of Pakistan by Jahanzaib Mughal.pdf
Origin of periodic table-Mendeleev’s Periodic-Modern Periodic table
PPT- ENG7_QUARTER1_LESSON1_WEEK1. IMAGERY -DESCRIPTIONS pptx.pptx
O7-L3 Supply Chain Operations - ICLT Program
Pharmacology of Heart Failure /Pharmacotherapy of CHF
Physiotherapy_for_Respiratory_and_Cardiac_Problems WEBBER.pdf
master seminar digital applications in india
Business Ethics Teaching Materials for college
O5-L3 Freight Transport Ops (International) V1.pdf
ANTIBIOTICS.pptx.pdf………………… xxxxxxxxxxxxx
Mark Klimek Lecture Notes_240423 revision books _173037.pdf
Saundersa Comprehensive Review for the NCLEX-RN Examination.pdf
Week 4 Term 3 Study Techniques revisited.pptx
GDM (1) (1).pptx small presentation for students
102 student loan defaulters named and shamed – Is someone you know on the list?
Basic Mud Logging Guide for educational purpose
Introduction to Child Health Nursing – Unit I | Child Health Nursing I | B.Sc...
2.FourierTransform-ShortQuestionswithAnswers.pdf
Pre independence Education in Inndia.pdf
Microbial diseases, their pathogenesis and prophylaxis

21 CFR Part 822 Post Marketing Surveillance.pptx

  • 1. SEMINAR PRESENTATION ON 21 CFR Part 822 Post Marketing Surveillance R. C. PATELINSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH PRESENTED BY: Mr. MayurAnil Patil M.PHARM 1ST YEAR MRA09 GUIDED BY : DR. P. P. NERKAR PROFESSORAND HEAD OF RADEPARTMENT
  • 2. Post Marketing Surveillance  The term Pharmacovigilance is used for the Post Marketing Surveillance of a drug. Post Marketing Surveillance helps to monitor the side effects of a drug after it has been launched in the market for the use of the patients.  Post Marketing Surveillanceis another term used for Pharmacovigilance.
  • 3. Table of Contents Subpart A - General Provisions $ 822.1 What does this part cover? $822.2 What is the purpose of this part? § 822.3 How do you define the terms used in this part? $822.4 Does this part apply to me ? Subpart B – Notification § 822.5 How will I know if I must conduct post market surveillance? § 822.6 When will you notify me that I am required to conduct post market surveillance? $822.7 What should I do if I do not agree that postmarket surveillance is appropriate?
  • 4. Subpart C-Post-Market Surveillance Plan• § 822.8When, where, and how must I submit my postmarket surveillance plan? § 822.9What must I include in my submission? § 822.10What must I include in my surveillance plan? § 822.11What should I consider when designing my plan to conduct postmarket surveillance? § 822.12Do you have any information that will help me prepare my submission or design my postmarket surveillance plan? § 822.13 [Reserved] § 822.14May I reference information previously submitted instead of submitting it again? § 822.15How long must I conduct postmarket surveillance of my device?
  • 5. Subpart D-FDA Review and Action. § 822.16What will you consider in the review of my submission? § 822.17How long will your review of my submission take? § 822.18How will I be notified of your decision? § 822.19What kinds of decisions may you make? § 822.20What are the consequences if I fail to submit a postmarket surveillance plan, my plan is disapproved and I fail to submit a new plan, or I fail to conduct surveillance in accordance with my approved plan? § 822.21What must I do if I want to make changes to my postmarket surveillance plan after you have approved it? § 822.22What recourse do I have if I do not agree with your decision? § 822.23Is the information in my submission considered confidential?
  • 6. Subpart E-Responsibilities of Manufacturers. § 822.24What are my responsibilities once I am notified that I am required to conduct postmarket surveillance? § 822.25What are my responsibilities after my postmarket surveillance plan has been approved? § 822.26If my company changes ownership, what must I do? § 822.27If I go out of business, what must I do? § 822.28If I stop marketing the device subject to postmarket surveillance, what must I do?
  • 7. Subpart F-Waivers and Exemptions. § 822.29May I request a waiver of a specific requirement of this part? § 822.30May I request exemption from the requirement to conduct postmarket surveillance? Subpart G-Records and Reports. § 822.31What records am I required to keep? § 822.32What records are the investigators in my surveillance plan required to keep? § 822.33How long must we keep the records? § 822.34What must I do with the records if the sponsor of the plan or an investigator in the plan changes? § 822.35Can you inspect my manufacturing site or other sites involved in my postmarket surveillance plan? § 822.36Can you inspect and copy the records related to my postmarket surveillance plan? § 822.37Under what circumstances would you inspect records identifying subjects? § 822.38What reports must I submit to you?
  • 8. Subpart A: General Provisions $ 822.1 What does this part cover? This part implements section 522 of the Federal Food, Drug, and Cosmetic Act (the act) by providing procedures and requirements for post market surveillance of class II and class III devices that meet any of the following criteria: • Failure of the device that would likely to have serious adverse health consequences • device is intended to be implanted in the human body for more than 1 year
  • 9. $822.2 What is the purpose of this part? ∙to implement our post market surveillance authority to maximize the likely hood that post market surveillance plans will result in the collection of useful data that can reveal unforeseen ADRs. § 822.3 How do you define the terms used in this part? • Act means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et seq., as amended. • Unique device identifier (UDI) means an identifier that adequately identifies a device through its distribution • Manufacturer • Investigator •PMS
  • 10. $822.4 Does this part apply to me ? If we have ordered you to conduct post market surveillance of a medical device under section 522 of the act, this part applies to you, if the MD’s intended use is any: • Implant for more than 1 year • Support or sustain life
  • 11. Subpart B: Notification § 822.5 How will I know if I must conduct post market surveillance? • FDA will send you a letter (the post market surveillance order) notifying you of the requirement to conduct post market surveillance. • FDA will specify the device(s) subject to the surveillance order and the reason for requiring post market surveillance of the device under section522 of the act.
  • 12. § 822.6 When will you notify me that I am required to conduct post market surveillance? • FDA will notify you as soon as we have determined that postmarket surveillance of your device is necessary, based on the identification of a surveillance question. $822.7 What should I do if I do not agree that postmarket surveillance is appropriate? • Requesting a meeting with the Director, Office of Surveillance and Biometrics • Requesting review by the Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee.
  • 13. Subpart C-Post-Market Surveillance Plan § 822.8 When, where, and how must I submit my postmarket surveillance plan? You must submit your plan to conduct post-market surveillance within 30days of the date you receive the post- market surveillance order to the following concerned authorities: • Center for Biologics Evaluation and Research, FDA • Center for Drug Evaluation and Research, FDA • Document Mail Center for Radiological Devices
  • 14. § 822.9 What must I include in my submission? 1.Organizational/administrative information: • Your name and address. • Generic and trade names of your device • Name and address of the contact person for the submission • Premarket application/submission number and device identifiers • Description of the device • Product codes and a list of all relevant model numbers • Indications for use and claims for the device 2. Post-market surveillance plan 3. Designated person information • Name, address, and telephone number • Experience and qualifications
  • 15. $822.10 What must I include in my surveillance plan? The plan objectives. • Subject of study (humans, animals). • Approach or methodology. • Sample size • Data collection plan. • Consent document • IRB approval • Content and timing of reports • Patient follow up plans • Duration
  • 16. §822.11 What should I consider when designing my plan to conduct postmarket surveillance? You must design your surveillance to address the post-market surveillance question identified in the order you received. § 822.12 Do you have any information that will help me prepare my submission or design my postmarket surveillance plan? Guidance documents that discuss our current thinking on preparing a post-market surveillance submission and designing a post-market surveillance plan are available on the Center for Devices and Radiological Health’s website, the Food and Drug Administration main website
  • 17. § 822.14 May I reference information previously submitted instead of submitting it again? Yes, you may reference information that you have submitted in premarket submissions as well as other post-market surveillance submissions, with document and page number. § 822.15 How long must I conduct post-market surveillance of my device? The length of post-market surveillance will depend on the post- market surveillance question identified. It may be of 36 months or more depending on satisfying information.
  • 18. Subpart D-FDA Review and Action. § 822.16 What will you consider in the review of my submission? First, we will determine that the submission is administratively complete. Then, in accordance with the law, we must determine whether the designated person has appropriate qualifications and experience to conduct the surveillance and whether the surveillance plan will result in the collection of useful data that will answer the surveillance question. § 822.17 How long will your review of my submission take? We will review your submission within 60 days of receipt. § 822.18 How will I be notified of your decision? We will send you a letter notifying you of our decision and identifying any action you must take. § 822.19 What kinds of decisions may you make?
  • 19. Subpart E—Responsibilities of Manufacturers § 822.24 What are my responsibilities once I am notified that I am required to conduct postmarket surveillance? You must submit your plan to conduct postmarket surveillance to us within 30 days from receipt of the order (letter) notifying you that you are required to conduct postmarket surveillance of a device. The manufacturer shall commence surveillance not later than 15 months after the day the order was issued. [88 FR 16880, Mar. 21, 2023] § 822.25 What are my responsibilities after my postmarket surveillance plan has been approved? After we have approved your plan, you must conduct the postmarket surveillance of your device in accordance with your approved plan. This means that you must ensure that: (a) Postmarket surveillance is initiated in a timely manner; (b) The surveillance is conducted with due diligence; (c) The data identified in the plan is collected; (d) Any reports required as part of your approved plan are submitted to us in a timely manner; § 822.26 If my company changes ownership, what must I do? You must notify us within 30 days of any change in ownership of your company. § 822.27 If I go out of business, what must I do? You must notify us within 30 days of the date of your decision to close your business. § 822.28 If I stop marketing the device subject to postmarket surveillance, what must I do? You must continue to conduct postmarket surveillance in accordance with your approved plan even if you no longer market the device.
  • 20. Subpart F—Waivers and Exemptions § 822.29 May I request a waiver of a specific requirement of this part? You may request that we waive any specific requirement of this part. You may submit your request, with supporting documentation, separately or as a part of your postmarket surveillance submission to the address in § 822.8. § 822.30 May I request exemption from the requirement to conduct postmarket surveillance? You may request exemption from the requirement to conduct postmarket surveillance for your device or any specific model of that device at any time.
  • 21. Subpart G—Records and Reports § 822.31 What records am I required to keep? You must keep copies of: (a) All correspondence with your investigators or FDA, including required reports; (b) Signed agreements from each of your investigators, if your surveillance plan uses investigators, stating the commitment to conduct the surveillance in accordance with the approved plan, any applicable FDA regulations, and any conditions of approval for your plan, such as reporting requirements; (c) Your approved postmarket surveillance plan, with documentation of the date and reason for any deviation from the plan; (d) All data collected and analyses conducted in support of your postmarket surveillance plan; § 822.32 What records are the investigators in my surveillance plan required to keep? Your investigator must keep copies of: (a) All correspondence between investigators, FDA, the manufacturer, and the designated person, including required reports. (b) The approved postmarket surveillance plan, with documentation of the date and reason for any deviation from the plan. (c) All data collected and analyses conducted at that site for postmarket surveillance. (d) Any other records that we require to be maintained by regulation or by order. § 822.33 How long must we keep the records? You, the designated person, and your investigators must keep all records for a period of 2 years after we have accepted your final report, unless we specify otherwise.
  • 22. § 822.34 What must I do with the records if the sponsor of the plan or an investigator in the plan changes? If the sponsor of the plan or an investigator in the plan changes, you must ensure that all records related to the postmarket surveillance have been transferred to the new sponsor or investigator and notify us within 10 working days of the effective date of the change. 822.36 Can you inspect and copy the records related to my postmarket surveillance plan? We may, at a reasonable time and in a reasonable manner, inspect and copy any records pertaining to the conduct of postmarket surveillance that are required to be kept by this regulation.
  • 23. § 822.37 Under what circumstances would you inspect records identifying subjects? We can inspect and copy records identifying subjects under the same circumstances that we can inspect any records relating to postmarket surveillance. § 822.38 What reports must I submit to you? You must submit interim and final reports as specified in your approved postmarket surveillance plan. In addition, we may ask you to submit additional information when we believe that the information is necessary for the protection of the public health and implementation of the act. We will also state the reason or purpose for the request and how we will use the information.